Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Sponsor:

McGill University

Code:

NCT06249867

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Darifenacin 7.5 MG Extended Release Oral Tablet

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information